Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.

Authors

MarnixMarnix Heimen Geukes Foppen

Netherlands Cancer Institute, Amsterdam, Netherlands

MarnixMarnix Heimen Geukes Foppen , Marco Donia , Troels Holz Borch , Özcan Met , Christian U. Blank , Loes Pronk , Johannes V. Van Thienen , Inge Marie Svane , John B. A. G. Haanen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

First Author: Amod Sarnaik

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).

First Author: Rodabe Navroze Amaria

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

First Author: Amod Sarnaik

insert_chart_outlined

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

bookmark_border

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.

First Author: Amod Sarnaik